Physician profile
John Jasinski
NPI 1598781791
$185,158.62
in general payments reported to CMS, 2019-2025
30 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $25K · 2023: $37K · 2024: $49K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Food and Beverage: $20K · Travel and Lodging: $8,373 · Consulting Fee: $3,818 · Education: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,704.25 |
| Food and Beverage | $19,551.06 |
| Travel and Lodging | $8,372.71 |
| Consulting Fee | $3,817.50 |
| Education | $305.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $57,685.64 | 2021-2025 | Tremfya |
| Incyte Corporation | $36,110.75 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $32,886.22 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $17,438.66 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $14,749.98 | 2022 | |
| Sun Pharmaceutical Industries INC. | $9,064.29 | 2021-2025 | Ilumya |
| Genzyme Corporation | $3,166.09 | 2021-2025 | |
| Pfizer INC. | $2,873.06 | 2021-2025 | |
| Leo Pharma INC. | $2,224.67 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $1,915.60 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,651.69 | 2021-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,449.36 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $924.52 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $804.11 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $352.12 | 2022-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $347.76 | 2021-2025 | Cabtreo, Jublia |
| Amgen INC. | $335.49 | 2021-2025 | Otezla, Enbrel, Otezla |
| Arcutis Biotherapeutics, INC. | $261.34 | 2024-2025 | Zoryve |
| Organon LLC | $220.15 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $168.30 | 2021-2025 | Aklief, Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.39 | 2024-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Blueprint Medicines Corporation | $71.67 | 2023-2024 | Ayvakit |
| Biofrontera INC. | $68.77 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $43.08 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $41.98 | 2023-2024 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $31.33 | 2021-2022 | |
| Medtronic, INC. | $24.96 | 2021 | |
| Allergan, INC. | $15.36 | 2021 | |
| Journey Medical Corporation | $15.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jasinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.